Open an account

Microbot Medical

MBOT · NASDAQ

$0.9475−$0.0053 (−0.56%)TodayMarket closed ·
Prev close $0.9528

About MBOT

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The company is headquartered in Hingham, Massachusetts and currently employs 43 full-time employees. The company has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. The company specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. The company eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.

Employees
43
Headquarters
Hingham, Massachusetts
Listed
Mar 25, 1992
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
microbotmedical.com

MBOT key statistics

Market cap
63.64M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
772.84K
Volume
724.52K
Open price
$0.9583
High today
$1.03
Low today
$0.945
52 Week high
$2.89
52 Week low
$0.93

Microbot Medical (MBOT) at a glance

As of Oct 20, 2026, Microbot Medical (MBOT) shares are priced at $0.9475, giving the company a market cap of 63.64M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.945 and $1.03. The current price is 0.3% above the day's low and 8.0% below its high.

Volume so far is 724.52K shares, in line with the average of 772.84K shares a day.

Over the past year Microbot Medical has ranged from $0.93 to $2.89, and now sits 1% of the way up that range.

Microbot Medical met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.08 per share against an estimate of -$0.0782.

The average analyst price target is $6.80, 617.7% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $6.80
Low
$4.04
Now
$0.9475
High
$12.60

MBOT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 34.3% on average.

  1. Q3 FY24: reported -$0.20 per share against an estimate of -$0.1734
  2. Q4 FY24: reported -$0.20 per share against an estimate of -$0.1836
  3. Q1 FY25: reported -$0.09 per share against an estimate of -$0.1326
  4. Q2 FY25: reported -$0.10 per share against an estimate of -$0.0816
  5. Q3 FY25: reported -$0.07 per share against an estimate of -$0.0612
  6. Q4 FY25: reported -$0.04 per share against an estimate of -$0.0612
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.0782
  8. Q2 FY26: reported -$0.08 per share against an estimate of -$0.0782

MBOT news

  • Press releaseGlobe Newswire

    Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System

  • Press releasePRNewswire

    MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

  • Press releaseGlobe Newswire

    Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System

  • Press releaseGlobe Newswire

    Microbot Medical®'s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference

  • Press releaseGlobe Newswire

    Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption

  • Press releaseGlobe Newswire

    Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones

  • Press releaseGlobe Newswire

    Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System

  • Press releaseGlobe Newswire

    Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.